Previous close | 259.11 |
Open | 259.90 |
Bid | 259.79 x 1400 |
Ask | 260.03 x 900 |
Day's range | 259.32 - 262.67 |
52-week range | 212.40 - 317.17 |
Volume | |
Avg. volume | 763,501 |
Market cap | 23.519B |
Beta (5Y monthly) | 1.03 |
PE ratio (TTM) | 12.58 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 2.88 (1.14%) |
Ex-dividend date | 17 Aug 2022 |
1y target est | N/A |
BURLINGTON, N.C., July 28, 2022--Labcorp (NYSE: LH), a leading global life sciences company, today announced results for the second quarter ended June 30, 2022, and updated full-year guidance.
BURLINGTON, N.C., July 28, 2022--Labcorp (NYSE: LH) (the "Company"), a leading global life sciences company, today announced that its Board of Directors has authorized the Company to pursue a spin-off of the Company’s wholly owned Clinical Development business to Labcorp shareholders through a tax-free transaction. The planned spin-off will result in two independent, publicly traded companies, each poised for strong, sustainable growth:
BURLINGTON, N.C., July 22, 2022--Labcorp (NYSE: LH), a leading global life sciences company, today announced that it scored 100, the highest score possible, on the 2022 Disability Equality Index® (DEI), a comprehensive benchmarking tool for measuring disability inclusion in the workplace. The DEI, a joint initiative by Disability:IN® and the American Association of People with Disabilities (AAPD), exists to help businesses make a positive impact on the unemployment and underemployment of people